In response to public comment on draft recommendations published last year, the USPSTF changed course and retained cotesting as an option.
Efforts are underway to standardize pharmacogenetic testing, but experts say more needs to be done to encourage broader acceptance of these recommendations.
A panel led by the FH Foundation recommends routine genetic testing for those with very high LDL cholesterol and a family history of high cholesterol or early heart attack.
The findings run counter to historical data and may provide fodder to reconsider current guideline recommendations on surveillance of colorectal cancer patients.
The WHO said that the list is intended to serve as a reference for countries to update or develop their own list of essential diagnostics.
The updated recommendations discuss testing for DNA repair gene mutations, MSI-H, and dMMR, as well as germline testing and counseling.
The guidelines are the first to attempt to specify which drugs are appropriate to test for routinely, guideline authors say.
Qualitative testing offers more specificity and sensitivity than current frontline immunoassay-based testing, the group said in its guidelines.
According to a presentation at the College of American Pathologists' annual meeting, around 62 percent of lab testing errors occur during the preanalytical phase.